Ignite Creation Date:
2024-05-06 @ 2:34 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02076646
Status:
UNKNOWN
Last Update Posted:
2022-04-14
First Post:
2014-02-24
Brief Title:
A Phase III Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Sponsor:
Philogen SpA
Organization:
Philogen SpA
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-07-31
Start Date Type:
ACTUAL
Primary Completion Date:
2016-05-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-06
Completion Date Type:
ESTIMATED
First Submit Date:
2014-02-24
First Submit QC Date:
February 26 2014
Study First Post Date:
2014-03-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-13
Last Update Post Date:
2022-04-14
Last Update Post Date Type:
ACTUAL